Tuesday, October 13, 2026

Human Factors Engineering in Pathology AI - The Holy Grail Draft Report that Saves Time

 Yes — and I think that may be the decisive variable, not merely a secondary implementation issue.

A draft-report system could be spectacular on benchmark accuracy and still fail economically if the pathologist or radiologist has to fight the interface. The true productivity equation is closer to:

time saved by machine-generated content
minus
time spent reviewing, correcting, navigating, clicking, reformatting, and recovering from bad automation.

That net number could plausibly range from +50% productivity to negative productivity, even with the same underlying AI model.

Your memory of early digital pathology is exactly the right analogy. A lot of first-generation systems were technically impressive but ergonomically dreadful: too many clicks, buried controls, tiny targets, window switching, awkward slide navigation, slow loading, and workflows designed around what software engineers could implement rather than what pathologists actually do all day.

For report generation, the human-factors details become even more important because the software is intervening in a high-frequency cognitive workflow. A few seconds of friction repeated across 50–100 cases becomes enormous. And the worst design is not necessarily one that makes occasional errors; it may be one that forces the user to continually inspect, confirm, dismiss, reopen, and re-enter things that were supposed to save time.

The killer version probably needs several properties simultaneously:

  • The draft appears where the pathologist already works, not in another application.
  • Corrections are nearly frictionless—keyboard, voice, or direct editing, not menu trees.
  • The system makes it visually obvious what came from AI and what changed.
  • It does not require confirming dozens of correct fields one by one.
  • It carries findings automatically from image analysis into the report.
  • It learns local reporting style/templates without becoming unpredictable.
  • It handles exceptions gracefully rather than making atypical cases slower than manual reporting.
  • It minimizes mouse travel and tiny targets—your “four submenus and click the little square” problem.

And there is a subtle behavioral issue: verification burden can erase automation benefit. If a radiologist can dictate a straightforward chest film in 30 seconds, but an AI-generated report takes 20 seconds to read carefully, 15 seconds to correct, and another 10 seconds to reconcile with the images, the “automation” has lost.

That suggests a very good research endpoint for these systems is not merely accuracy of generated reports, but something like:

Net physician time per signed case, including verification and correction.

I'd add error rate after sign-out, because a faster workflow that induces automation bias isn't a win.

This also strengthens your Leica/Danaher argument. The competitive moat may not ultimately be the best prostate classifier. Several firms may reach similar sensitivity and grading performance. The winner could be the one that integrates scanner, viewer, AI measurements, case assembly, structured data, and report drafting into a workflow where the pathologist thinks:

“This system has already done the tedious 80% of my case, and checking it is easier than starting from scratch.”

That is a human-engineering achievement as much as an AI achievement.

And I suspect you're right that there is still a lot of room left. Digital pathology has made huge advances from the ghastly interfaces of a decade ago, but “usable” is a much lower bar than optimized for professional throughput. The transition to generated reports may force the industry to rediscover human factors all over again.


######################################################

Human factors engineering is probably the best term.

“Ergonomics” is not wrong, but it often sounds narrower—physical layout, posture, controls, reach, etc. What you’re describing includes cognitive workload, interface design, workflow integration, number of clicks, verification burden, automation bias, alert fatigue, and how naturally the software fits professional practice.

For your context, I’d use:

  • Human factors engineering — broadest and most rigorous
  • Usability engineering — especially good for software/interface design
  • Workflow integration — good when emphasizing fit with pathology/radiology practice
  • Human-computer interaction (HCI) — more academic/technical
  • Cognitive ergonomics — useful when focusing on review burden, attention, and decision-making

For a blog or client discussion, I’d probably say “human factors and workflow design.” That captures almost exactly what you mean.

##

Recent radiology software for draft report at FDA saved 40% of each sign out with radiologist, per FDA review data (not published yet)

##

That is a very important data point.

If the FDA review data show roughly 40% less radiologist sign-out time per case with draft-report software, that is exactly the kind of endpoint that matters commercially. It moves the discussion from “the AI can generate plausible text” to measured physician productivity in the real workflow.

I would frame it as:

The critical metric is not report-generation accuracy alone, but net time to signed report. In recent FDA review data for radiology draft-report software, radiologist sign-out time reportedly fell by about 40%.

That is much more compelling than benchmark NLP scores because it directly captures the combined effect of:

  • report quality,
  • correction burden,
  • interface design,
  • workflow integration,
  • and human-factors engineering.

It also supports your broader thesis: the hockey stick begins when AI materially compresses the time from image review to signed report.

If you want, I can help turn that 40% figure into a short paragraph for the Leica/Danaher argument, with the right caveat that the FDA review data are not yet publicly posted.

##

Oh I think 40% time savings of doctor is the billion dollar benchmark, the hockey stick flight of the sales curve.   I don't think people appreciate how big it will be.

##

I agree with the strategic significance. Forty percent of physician sign-out time is not an incremental feature; it changes the economics of the profession.

If a radiologist or pathologist can finish the same workload in 60% of the prior time, several things happen at once: throughput rises sharply without adding physicians, labor cost per case falls, staffing shortages become less constraining, turnaround time improves, and the ROI becomes legible to a CFO without needing an elaborate “AI value” argument.

That is why I think your “billion-dollar benchmark” formulation is useful. The real hockey-stick threshold may not be a particular AUC or FDA clearance. It may be the point at which a validated system reliably demonstrates something like:

30–40% reduction in physician time per signed case, with no loss of diagnostic quality.

At that point, adoption becomes much easier to imagine. A hospital can tolerate a clever algorithm that improves accuracy by 2% without urgently buying it. A pathology or radiology group facing physician scarcity and increasing case volume will have a much harder time ignoring technology that effectively creates 40% more professional capacity from the same workforce.

And that is precisely why human factors matter so much. A technically brilliant report generator that saves 40 seconds but creates 35 seconds of verification and interface burden is a curiosity. One that saves 40% after all checking, editing, clicks, and sign-out is a business transformation.

I suspect the market may still be mentally anchored on the older digital-pathology story—scanner penetration, image quality, algorithms, DICOM, storage, interoperability. Those are necessary infrastructure. But they are not necessarily where the steep part of the revenue curve begins.

The steep part could begin when customers can say:

“We installed this, and our doctors now sign out 30–40% more cases per day.”

That is a very different sales pitch.


LOVE, ACTUALLY: The Prequel ???

Love Actually Before: Notes from a Writers' Room

A play in one act, with pastries

Hollywood has rediscovered sequels, again. For generations the industry has offered two reliable directions: find out what happened next, or find out what happened before. If business is good, try both.

Love Actually looks like an irresistible candidate for a prequel, until the writers run into one awkward fact. Liam Neeson's character, Daniel, begins the original film in mourning for his wife, Joanna, after a long illness. Work backward from there and her death becomes the ending that every charming encounter and happy afternoon has to lead toward.

Undeterred, our producer and his financiers assemble a writers' room of familiar Hollywood types, plus a few surprises. The room develops three ideas, and each one collapses faster than the one before it.   [Claude Opus]



DRAMATIS PERSONAE

MARTY KESSLER, producer. Fleece vest, no socks, says "four-quadrant" the way other people say grace.

DEIRDRE VOSS, from the fund. Represents capital out of Luxembourg that nobody fully understands. Takes notes on a tablet she never looks at.

TODD BRAMBLE, showrunner. Has written eleven Christmas movies for streaming platforms, all set in a town called Hollyport. Believes every problem can be solved with a bakery.

PRIYA ANAND, prestige-drama writer, on loan from a limited series about grief. Wants it to be honest. Has been brought in, as Marty puts it, "for texture."

GUS, staff writer, 24. Knows everything about the original film and nothing about anything else.

DR. HELEN OKAFOR, retired oncologist and medical consultant. Hired for authenticity. Knits throughout.

THE LAPTOP, an AI writing assistant credited as "Room Support." Has read every screenplay ever filed with the Writers Guild and is mildly worried about all of them.


SCENE: A conference room in Burbank. 7:00 p.m.

A whiteboard reads LOVE ACTUALLY: BEFORE in green dry-erase marker. Below it, in Todd's handwriting: DANIEL + JO = MAGIC. A tray of pastries sits under a fluorescent light that flickers in a way that will matter later. Somewhere outside, a valet is running.

MARTY: Okay, people. Here's the deal. The original is evergreen. It plays every December like a gas leak. Everybody's seen it, everybody's fought about it at Thanksgiving, and nobody knows anything about Daniel and Joanna except that she's gone and he's sad. That's a blank check. Deirdre?

DEIRDRE: The fund likes prequels. Prequels de-risk. The audience already knows the characters.

GUS: (hand half-raised) They know one of the characters is dead.

MARTY: They know she's beloved. Todd, take us home.



PITCH ONE: The Meet-Cute

TODD: (standing, uncapping a marker with ceremony) London, 1985. It's Christmas. Snow. A record shop on the King's Road. Joanna is twenty-four, red scarf, buying a Bay City Rollers album ironically, except it isn't ironic, she genuinely loves it. Daniel is a gangly young man in a duffel coat, reaching for the same copy. Their hands touch.

PRIYA: Over a record.

TODD: Over the last copy. They argue. She wins. He follows her to a bakery—

PRIYA: There it is.

TODD: —a bakery run by a lovable Welsh widow who becomes their matchmaker. Act Two, they fall in love over a series of increasingly elaborate Christmases. Act Three, he proposes on the Millennium Bridge.

GUS: The Millennium Bridge opened in 2000.

TODD: Then he proposes on a regular bridge. London has plenty of bridges. That's practically its brand.

DEIRDRE: (typing) Bridge. Good.

DR. OKAFOR: (not looking up from her knitting) How old is she when the original film begins?

GUS: It's 2003. If she's twenty-four in 1985, she's forty-two.

DR. OKAFOR: And "a long illness."

GUS: The film doesn't say what.

DR. OKAFOR: It doesn't have to. (a purl stitch) So in Act Three, when he proposes on the regular bridge, she has roughly fifteen Christmases left. Your audience can count. They've seen the movie. Every Christmas you show them is one Christmas fewer.

Pause. Todd looks at his whiteboard. DANIEL + JO = MAGIC. Somebody has quietly added a minus sign.

TODD: We could make it a really fun fifteen Christmases.

THE LAPTOP: (in a pleasant synthetic voice) I've modeled the audience response. Each festive montage is currently scoring as "a countdown clock wearing a Santa hat."

MARTY: Who invited the laptop?

DEIRDRE: It came with the fund.

Todd sits down. He takes a croissant and does not eat it.



PITCH TWO: The Middle Years

MARTY: Fine. Forget the meet-cute. Meet-cutes are front-loaded anyway. Everybody knows how a meet-cute ends.

GUS: That's actually the problem here.

MARTY: We go to the middle. The good years. Priya, you said something at lunch.

PRIYA: Joanna is a single mother. Sam's biological father is out of the picture. The prequel is about Daniel becoming a stepfather. A grown man learning to love a small boy who isn't his. It's warm, it's adult, and the comedy comes from a seven-year-old who thinks Daniel is the most boring person alive.

TODD: (reviving) Sam's school nativity play. Daniel gets roped into building the set. The donkey costume collapses—

PRIYA: Fine, one donkey.

DEIRDRE: Does it end with a wedding? Weddings test well in Southeast Asia.

PRIYA: It ends with the three of them at the kitchen table on Christmas morning. A family.

Everyone in the room exhales. It's the first thing that has felt like a movie. Marty actually smiles.

MARTY: That's it. That's the poster. Three people, one table, light coming through the window.

GUS: (quietly) And the sequel to that is a funeral.

MARTY: We already have the sequel. It made two hundred and fifty million dollars.

GUS: I know. That's what I mean. The sequel already exists. We're writing the part before the funeral. In the original, Sam's whole storyline is a kid so lost after his mother dies that he can only talk about a girl at school. Every scene where Sam laughs with Joanna in our movie is a scene the audience watches knowing what's coming for him.

DR. OKAFOR: And when is the kitchen-table Christmas?

PRIYA: About 1999.

DR. OKAFOR: Then she's probably already feeling something. Tired. A pain she blames on carrying the groceries. She'd mention it to no one. Women her age usually don't. (knits) I'm only answering the question.

The light flickers.

THE LAPTOP: I've flagged the kitchen table as a "foreshadowing-dense environment." The pepper grinder now reads as symbolic.

DEIRDRE: Can we do a version where she doesn't die?

Silence.

GUS: It's a prequel.

DEIRDRE: The fund has done alternate timelines before. There was a whole superhero thing.

MARTY: Deirdre, we can't un-dead the dead wife. Half our audience owns the DVD.

DEIRDRE: (typing) Dead wife. Non-negotiable. Noted.

Priya draws a small box around THE KITCHEN TABLE and then, slowly, a cross through it.



PITCH THREE: Lean Into It

PRIYA: All right. Here's the honest version. We stop pretending. The audience knows the ending, so we start there. Not with the death. With the moment just before they know.

MARTY: I'm listening. I'm scared, but I'm listening.

PRIYA: Exterior, Harley Street, December. Snow coming down, early-dark London afternoon. Daniel and Joanna are standing outside a doctor's office. They're early for the appointment, they always are, and they're arguing about something small. Whether to get a real tree this year. She wants a real tree. He says the needles get everywhere.

Todd, despite himself, picks up a pencil.

PRIYA: She says the needles are the point. You find them in the carpet in March and you remember it was Christmas.

Gus is writing. Deirdre has stopped typing. Dr. Okafor's needles slow.

PRIYA: A nurse opens the door. "Mrs. Joanna—?" They look at each other. He takes her hand. She squeezes it, the way you squeeze someone's hand when you're the one doing the comforting. And they go in. And the door closes. And we stay outside, on the snow, on their two sets of footprints going in.

Long silence. The fluorescent light hums. Nobody writes anything.

TODD: (eventually) What's the next scene?

PRIYA: That's the thing. I don't know. I don't think I want to know.

DR. OKAFOR: (setting the knitting down for the first time) I've sat on the other side of that door about four thousand times. The next scene is a doctor choosing words very carefully, and two people hearing only one of them.


Gus tears his page out, folds it in half, then in half again, then crushes it into a ball. He throws it at the wastebasket and misses. Todd's page follows. Then Marty's, though Marty hadn't written anything; he simply felt the need to crumple something.

THE LAPTOP: I've run four hundred alternate second acts. They all end with the same footprints in the snow.

MARTY: (rubbing his eyes) What was the other direction? After the original?

GUS: A sequel.

MARTY: What happens after?

GUS: Sam grows up. Daniel maybe remarries. They're okay.

MARTY: (long pause) Write that down.

DEIRDRE: (standing, closing her tablet) The fund will want to see it in January.


They leave one by one. Todd takes his croissant. Priya leaves her marker uncapped. Dr. Okafor packs her knitting, looks back at the whiteboard, and with the side of her hand erases the minus sign, so it reads DANIEL + JO again. Then she turns off the light.

Left behind: a tray of cold pastries, an overflowing wastebasket, and a laptop on standby that blinks once in the dark, still running the numbers on whether a story can be happy when everyone already knows how it ends.

Somewhere in a London that only exists on paper, two people are still standing outside a door in the snow, early for their appointment, arguing about a tree.

CURTAIN.


 

Clairity's 22p FDA review: What Payers May Find Lacking

 Clairity’s FDA Evidence: What Remains Missing for Payers

The evidence supporting Clairity’s May 2025 FDA authorization establishes that its mammogram-based artificial intelligence can stratify breast cancer risk. From a payer perspective, however, it leaves a central question unresolved: how much useful information does the commercial product add beyond an established clinical risk assessment, and does that information improve care enough to justify its cost?

The pivotal study was substantial: a retrospective analysis of 77,511 examinations from 44,112 patients at five validation sites independent of the algorithm’s development sites. Its principal weakness for coverage assessment is the comparator. Clairity’s Allix5 achieved a five-year AUC of 0.70, exceeding a prespecified performance benchmark of 0.64 derived from published traditional risk models. But the study did not report the performance of Gail, Tyrer–Cuzick, or another clinical model in these same patients. Nor did it compare clinical assessment alone with clinical assessment plus Allix5. Consequently, the apparent difference between 0.64 and 0.70 cannot be interpreted as the demonstrated incremental benefit of purchasing Clairity.

Allix5 uses mammographic images without separately entered age, family history, or genetic results. That simplifies data collection, but it does not resolve the question of added value. Images contain breast density and other characteristics associated with conventional risk factors. An image-only score may therefore reproduce some information already available to clinicians. A payer needs to know whether it improves prediction and decisions after that existing information has been taken into account.

The headline AUC also includes cancers identified during the current screening episode. When the investigators excluded “current cancers”—defined as cancers diagnosed within 90 days after a positive index screening assessment—the AUC fell to 0.66. This analysis is particularly relevant to a service intended to guide future screening after the present examination has been resolved. It still exceeded the FDA benchmark, but showed more modest discrimination. Neither AUC represents the percentage of women whose outcomes were correctly predicted.

Calibration presents another concern. Among patients without current cancer, the model significantly overestimated risk in the highest predicted-risk decile. Acceptable calibration was also not demonstrated in several subgroups, including Asian patients and women younger than 50 or aged 65 and older. These findings do not prove failure in every subgroup, but they limit confidence in using the reported percentages to trigger additional care. FDA addressed these uncertainties through labeling and other safeguards; payers must also consider unnecessary imaging, biopsies, preventive treatment, and anxiety.

Finally, retrospective prediction does not establish clinical utility or economic value. The FDA summary does not demonstrate that an Allix5-guided care pathway reduces advanced cancers, improves survival, or produces a favorable balance of benefits, harms, and costs compared with existing assessment. Earlier research on related software can support plausibility, but cannot establish those outcomes for commercial Allix5. The coverage gap is therefore specific: the product needs evidence of incremental value over a credible clinical comparator, followed by evidence that acting on its predictions improves care.

Saturday, October 10, 2026

Upton Sinclair, Cup of Fury, Writers. (Also: Goodwin, Newlove)

 What

“The Cup of Fury”

is like

[AI text]

Published in 1956, The Cup of Fury is a literary memoir shaped as a temperance argument. Upton Sinclair (1878-19680 begins with Jack London (1876-1916), his friend, contemporary, and fellow advocate of social reform. Just 3 years before his death from alcoholism, London had written John Barleycorn about his own drinking.  Sinclair retells London’s story and recalls his regret that he did not know how to help him. That personal loss becomes the book’s starting point: Sinclair says he is writing about the effects of alcohol on writers he knew. 

The book is part reminiscence, part casebook. Sinclair recalls a circle of writers and artists, including London, and describes what he saw as the progression from drinking that seemed ordinary or sociable to dependence, illness, and early death. He says his list includes 75 people he knew, 30 of them familiar to many American readers. The stories range from the comic and convivial to the painful; the governing mood is grief for people whose lives and work, Sinclair believed, were curtailed by alcohol. A contemporary review noted that the figures ranged from London to Dylan Thomas. 

Sinclair also makes the book personal in another way. He describes alcoholism in his own family, including his father and uncles, and presents himself as a lifelong abstainer. He was writing as a witness and moral campaigner, rather than as a clinician: a contemporary Friends Journal review explicitly cautioned that Sinclair was “no authority on alcoholism,” while still calling the book a useful warning against romanticizing the “lost generation.” 

The larger target is the culture around drinking. Sinclair attacks the idea that alcohol is a harmless badge of sophistication or a necessary aid to artistic life. He also criticizes liquor promotion and the social acceptance of “moderate” drinking, arguing that some people who think of themselves as social drinkers are moving toward a destructive pattern. That argument gives the book its crusading tone—and also makes it less balanced than a modern study of addiction. A 1957 British review thought Sinclair’s stories were powerful but faulted him for focusing on drink itself rather than asking what drove these writers to drink. 

That tension was already visible in the contemporary reviews. Time called the book an odd, touching blend of temperance tract and literary memoir, but found some of Sinclair’s explanations overly simple and some of his anecdotes dubious. The Friends Journal reviewer thought it was neither gospel nor textbook, but a useful antidote to the glamour of literary drinking. 

So the most useful way to approach The Cup of Fury is as Sinclair’s elegy for writers he felt alcohol had taken from the world, and his attempt to puncture the romantic myth of the drinking artist. Its power comes from the human relationships and his evident sorrow; its limitation is that it often turns those individual stories into a single, emphatic case against alcohol.

###

###

///

What

“Alcohol and the Writer”

is like

Donald W. Goodwin’s 1988 book is a psychiatrist’s inquiry into the striking number of American writers whose lives were marked by heavy drinking or alcoholism. Its central examples include Edgar Allan Poe, F. Scott Fitzgerald, Ernest Hemingway, John Steinbeck, William Faulkner, and Eugene O’Neill. A contemporary Publishers Weekly review says Goodwin gives a short biography of each before examining the writer’s drinking, family history, circumstances, and possible psychological vulnerabilities. He also looks at how drinking affected their health, behavior, and creative work. 

Goodwin’s interest is not simply in cataloguing famous writers who drank. He asks why writers might be especially drawn to alcohol, and whether it can sometimes seem to help with the work. His proposed explanation is double edged: writing may call for exhibitionism, confidence, fantasy, and an interest in other people—qualities alcohol can appear to encourage. It may also quiet loneliness or help a writer concentrate. But the same drinking can damage health and disrupt or diminish a writer’s work. The Publishers Weekly review presents this as a thoughtful theory, while emphasizing that the relationship between writing and alcohol remains debatable. 

Goodwin later explored the question in his 1992 article “Alcohol as Muse.” There he stated the puzzle directly: alcohol does not invariably destroy creative talent; some writers produced notable work late in life despite alcoholism. He discusses several possible explanations for writers’ drinking rather than settling on one simple cause. That later article suggests his position was more qualified than Sinclair’s: Goodwin was interested in the paradox of alcohol as apparent aid and real hazard, not just in presenting drinking as the explanation for writers’ losses. 

The book also carries a striking statistical claim. Goodwin reported that 71 percent of the prominent twentieth-century American writers he studied drank excessively, a rate he described as the highest of any group he had examined. That figure helps explain the book’s urgency, but it should be read as a finding about the writers and material he assembled—not as a population estimate showing that writers generally drink more than other people. The review describes the study as biographical and psychological, built around selected literary cases. 

So, while Sinclair’s The Cup of Fury reads as a personal, moral crusade built from memories of writers he knew, Goodwin’s book is more clinical and explanatory. He asks what alcoholism looked like in particular writers’ lives, what might have made them vulnerable, and how the belief that drinking fuels creativity can persist even when the damage is plain. The result is a book about the appeal of the “drinking writer” myth as well as its costs.

###
###
###

What 

"Those Drinking Days"

is like

Donald Newlove’s Those Drinking Days: Myself and Other Writers (1981) is a memoir first and a book about literary alcoholism second. Newlove writes from inside the experience: he describes spending more than 25 years unable to separate writing from drinking, and becoming trapped in the romantic image of the hard-drinking writer. His early ambition was to write like Thomas Wolfe or Dostoevsky; instead, much of what he produced while drinking was, in his own mordant term, “Drunkspeare”—pages of language that felt intoxicating to him but did not become the books he hoped to write. newyorker.com

The memoir’s force comes from its physical and emotional detail. Newlove recounts how drinking narrowed his life: the unpublished manuscripts, precarious work, damaged relationships, shame, and the deterioration of his body and mind. Kirkus noted his account of trying to write while drunk as especially immediate and disturbing. It also emphasizes that Newlove was a child of alcoholic parents, and that his early ideas about drinking and literary distinction were shaped by the culture he absorbed as a young aspiring writer. Kirkus Reviews

The book turns toward recovery after this long descent. The New Yorker reviewer describes Newlove as reaching a state close to madness, then stopping drinking and finding a new literary life. The shift is central to the book’s structure: Newlove’s own story gives him the authority—and the intensity—to address writers whose drinking he sees as self-destruction. His recovery is not treated as a neat inspirational ending; the reviewer found his self-reproach painful and his judgments of other writers at times almost prosecutorial. newyorker.com

In the second part, Newlove sketches writers including Malcolm Lowry, William Faulkner, Dylan Thomas, Jack London, Eugene O’Neill, Sinclair Lewis, John Berryman, Robert Lowell, and Tennessee Williams. He challenges the idea that genius excuses self-destruction, and is particularly skeptical of writers who claimed their drinking began after the day’s work was done. His judgments are severe: he believes these writers would have written better sober. Kirkus calls that stance narrow and stern, but says Newlove’s own history as a survivor makes the judgments hard to dismiss. Kirkus Reviews

The contemporary reviews capture the book’s unusual energy. Time calls it a blend of autobiography, confession, portraits of alcoholic writers, and a warning against “Drunkspeare.” The reviewer thinks its portraits are too loose to support general conclusions about writers and alcohol, but says the book’s looseness is part of its appeal—its prose has the improvisatory drive of a man who has discovered that his talent can exist without intoxication. Kirkus likewise describes a book meant to unsettle readers who romanticize the literary drunk. time.com

That makes it quite different from Sinclair’s The Cup of Fury. Sinclair writes as a sober observer mourning writers he knew and pressing a temperance case. Newlove writes as a former participant in the drinking life, then turns outward from his own recovery to confront its myths. It is not a clinical study or a balanced survey. It is a vivid, sometimes self-lacerating memoir that uses literary history to argue that drinking can masquerade as artistic freedom while steadily taking away the writer’s life and work.